Osteopore (ASX:OSX) Interest Paid: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Osteopore Interest Paid?

Osteopore ASX:OSX Interest Paid is A$0.00 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Osteopore's Interest Paid for the six months ended in Dec. 2025 was A$0.17 Mil.

Osteopore's Interest Paid for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Osteopore Interest Paid Related Terms

Osteopore Interest Paid Historical Data

* Premium members only.

The historical data trend for Osteopore's Interest Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osteopore Interest Paid Chart

Osteopore Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Paid
Get a 7-Day Free Trial -0.02 -0.01 -0.02 -0.43 0.00

Osteopore Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Paid Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.21 -0.22 -0.17 0.17

Osteopore Interest Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Paid represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Interest Paid for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Paid →
What does a Interest Paid of A$0.00 Mil mean?
Osteopore (ASX:OSX) has a Interest Paid of A$0.00 Mil as of Dec. 2025. Interest Paid represents interest paid on loans, debt or borrowings in direct cash flow method. View historical data for Osteopore and its competitors.
Is Osteopore's Interest Paid too high?
Osteopore's current Interest Paid is A$0.00 Mil.
How does Osteopore's Interest Paid compare to ISRG and BDX?
Osteopore's Interest Paid of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Paid for a Medical Devices & Instruments company?
A good Interest Paid depends on the Medical Devices & Instruments industry context. However, Interest Paid should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Paid mean?
A high Interest Paid can signal that a stock is expensive relative to its fundamentals. Interest Paid represents interest paid on loans, debt or borrowings in direct cash flow method. View historical data for Osteopore and its competitors. Osteopore's current Interest Paid is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current Interest Paid is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Paid calculated?
Interest Paid is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Interest Paid is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Osteopore Business Description

Address 2 Tukang Innovation Grove, No. 09-06 and 07, JTC MedTech Hub, Singapore, SGP, 618305
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.